Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
For Investors +
Join Us

Press Releases

Year

October 21, 2026

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

October 21, 2026

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

September 23, 2026

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 8, 2026

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

September 6, 2026

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

August 27, 2026

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

August 26, 2026

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

August 6, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 6, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

July 23, 2026

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2026 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn